Key result
Mitochondrial dysfunction and senescence drive arterial calcification, highlighting senolytics and PARP inhibitors.
Why the study?
Arterial calcification increases with age, contributes to vessel stiffening, and is associated with adverse cardiovascular outcomes independently of atherosclerosis and hyperlipidemia.
Design
Review
Authors
Loading...
Senolytics and PARP inhibitors merit investigation for age-related calcification; leaves open clinical translation pending prospective trials.
This review highlights emerging mechanisms of age-associated arterial calcification, such as mitochondrial dysfunction and cellular senescence, and identifies potential therapeutic targets to mitigate vessel stiffening.
Chakrabarti et al. (2020) conducted a review in Age-associated arterial calcification. Mitochondrial dysfunction, cellular senescence, and hyperglycemia promote age-determined arterial calcification, highlighting potential therapeutic targets like senolytics and PARP inhibitors.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: